Literature DB >> 20163272

Daptomycin: pharmacology and clinical use.

Christos Kosmidis1, Donald P Levine.   

Abstract

IMPORTANCE OF THE FIELD: Infections caused by Gram-positive organisms have increased in frequency and severity. Daptomycin offers a therapeutic option in an era of increasing resistance. AREAS COVERED IN THIS REVIEW: Literature from 1986 to present was reviewed for pharmacological, preclinical and clinical studies on daptomycin. WHAT THE READER WILL GAIN: The pharmacological properties, resistance mechanisms and clinical applications of daptomycin are discussed. Recommendations are offered on the use of this agent for the treatment of resistant Gram-positive infections. TAKE HOME MESSAGE: Daptomycin is a reliable agent for the treatment of Gram-positive infections. It has been shown to be effective in bacteremia and endocarditis, as well as in soft-tissue infections caused by Gram-positive organisms. Its role in the treatment of bone and joint infections is not well-defined. Resistance is currently uncommon in clinical isolates. However, emergence of resistance during therapy is a concern. This may be prevented by use of higher doses.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20163272     DOI: 10.1517/14656561003598893

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  10 in total

1.  Serum levels of daptomycin in pediatric patients.

Authors:  C Antachopoulos; E Iosifidis; K Sarafidis; F Bazoti; E Gikas; A Katragkou; V Drossou-Agakidou; E Roilides
Journal:  Infection       Date:  2012-01-21       Impact factor: 3.553

Review 2.  Eosinophilic pneumonia in patients treated with daptomycin: review of the literature and US FDA adverse event reporting system reports.

Authors:  Peter W Kim; Alfred F Sorbello; Ronald T Wassel; Tracy M Pham; Joseph M Tonning; Sumathi Nambiar
Journal:  Drug Saf       Date:  2012-06-01       Impact factor: 5.606

3.  Daptomycin versus vancomycin in a methicillin-resistant Staphylococcus aureus endophthalmitis rabbit model: bactericidal effect, safety, and ocular pharmacokinetics.

Authors:  Sophie Lefèvre; Maher Saleh; Luc Marcellin; Audrey Subilia; Tristan Bourcier; Gilles Prévost; François Jehl
Journal:  Antimicrob Agents Chemother       Date:  2012-02-27       Impact factor: 5.191

4.  Light-activated molecular machines are fast-acting broad-spectrum antibacterials that target the membrane.

Authors:  Ana L Santos; Dongdong Liu; Anna K Reed; Aaron M Wyderka; Alexis van Venrooy; John T Li; Victor D Li; Mikita Misiura; Olga Samoylova; Jacob L Beckham; Ciceron Ayala-Orozco; Anatoly B Kolomeisky; Lawrence B Alemany; Antonio Oliver; George P Tegos; James M Tour
Journal:  Sci Adv       Date:  2022-06-01       Impact factor: 14.957

5.  Membrane Binding and Oligomerization of the Lipopeptide A54145 Studied by Pyrene Fluorescence.

Authors:  TianHua Zhang; Scott D Taylor; Michael Palmer; Jean Duhamel
Journal:  Biophys J       Date:  2016-09-20       Impact factor: 4.033

6.  Eosinophilic pneumonia associated with daptomycin: a case report and a review of the literature.

Authors:  Andreas S Kalogeropoulos; Sotirios Tsiodras; Dionysios Loverdos; Panagiotis Fanourgiakis; Athanasios Skoutelis
Journal:  J Med Case Rep       Date:  2011-01-17

7.  Dose-dependent artificial prolongation of prothrombin time by interaction between daptomycin and test reagents in patients receiving warfarin: a prospective in vivo clinical study.

Authors:  Makoto Saito; Shuji Hatakeyama; Hideki Hashimoto; Takumitsu Suzuki; Daisuke Jubishi; Makoto Kaneko; Yukio Kume; Takehito Yamamoto; Hiroshi Suzuki; Hiroshi Yotsuyanagi
Journal:  Ann Clin Microbiol Antimicrob       Date:  2017-04-11       Impact factor: 3.944

8.  Comparative Metabologenomics Analysis of Polar Actinomycetes.

Authors:  Sylvia Soldatou; Grímur Hjörleifsson Eldjárn; Andrew Ramsay; Justin J J van der Hooft; Alison H Hughes; Simon Rogers; Katherine R Duncan
Journal:  Mar Drugs       Date:  2021-02-10       Impact factor: 5.118

9.  Daptomycin versus vancomycin for osteoarticular infections due to methicillin-resistant Staphylococcus aureus (MRSA): a nested case-control study.

Authors:  S Y Liang; H N Khair; J R McDonald; H M Babcock; J Marschall
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-11-03       Impact factor: 5.103

10.  Daptomycin to bone and joint infections and prosthesis joint infections: a systematic review.

Authors:  João Paulo Telles; Juliette Cieslinski; Felipe Francisco Tuon
Journal:  Braz J Infect Dis       Date:  2019-06-14       Impact factor: 3.257

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.